Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience

Nivolumab, a PD-1 checkpoint inhibitor, was approved in Canada in 2017 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the phase 3 trial CHECKMATE-141. We aimed to examine the demographics and efficacy of nivolumab in a Canadian, real-world set...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Yue (Jennifer), Fu, Rui, Levinsky, Justin T., Kamalraj, Pabiththa, Chan, Kelvin K. W., Parmar, Ambica, Eskander, Antoine, Smoragiewicz, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604932/
https://www.ncbi.nlm.nih.gov/pubmed/37887545
http://dx.doi.org/10.3390/curroncol30100645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604932/
https://www.ncbi.nlm.nih.gov/pubmed/37887545
http://dx.doi.org/10.3390/curroncol30100645

Ejemplares similares